.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 8,067,416

« Back to Dashboard

Claims for Patent: 8,067,416

Title:Methods and compositions for the treatment of metabolic disorders
Abstract: The present invention is directed to a novel methods and compositions for the therapeutic intervention in hyperphenylalaninemia. More specifically, the specification describes methods and compositions for treating various types of phenylketonurias using compositions comprising BH4. Combination therapies of BH4 and other therapeutic regimens are contemplated.
Inventor(s): Oppenheimer; Daniel I. (Castro Valley, CA), Kakkis; Emil D. (Novato, CA), Price; Fredric D. (Bedford, NY), Dorenbaum; Alejandro (Mill Valley, CA), Moser; Rudolf (Schaffhausen, CH), Groehn; Viola (Dachsen, CH), Egger; Thomas (Kempthal, CH), Blatter; Fritz (Reinach, CH)
Assignee: Merck Eprova AG (Schaffhausen, CH) Biomarin Pharmaceutical Inc. (Novato, CA)
Application Number:12/508,209
Patent Claims: 1. A method for treating a subject with hyperphenylalaninemia comprising administering to said subject a therapeutically effective amount of tetrahydrobiopterin (BH4) or pharmaceutically acceptable salt thereof, wherein the BH4 is administered orally once per day.

2. The method of claim 1, wherein the hyperphenylalaninemia results from BH4 deficiency.

3. The method of claim 1, wherein the hyperphenylalaninemia results from phenylketonuria (PKU).

4. The method of claim 1, 2 or 3, wherein said subject is administered BH4 for at least 7 days.

5. The method of claim 1, 2 or 3, wherein the subject is administered BH4 for at least 2 weeks.

6. The method of claim 1, 2 or 3, wherein said subject is administered BH4 for at least 6 weeks.

7. The method of claim 1, wherein said subject has a plasma phenylalanine concentration of greater than 180 .mu.M prior to treatment with BH4.

8. The method of claim 1, wherein said subject has a plasma phenylalanine concentration of greater than 600 .mu.M prior to treatment with BH4.

9. The method of claim 1, wherein said subject has a plasma phenylalanine concentration of greater than 1000 .mu.M prior to treatment with BH4.

10. The method of claim 1, wherein said subject has a plasma phenylalanine concentration of greater than 1200 .mu.M prior to treatment with BH4.

11. The method of claim 1, wherein said administration of BH4 decreases the plasma phenylalanine concentration of said subject to less than 600 .mu.M.

12. The method of claim 1, wherein said administration of BH4 decreases the plasma phenylalanine concentration of said subject to less than 500 .mu.M.

13. The method of claim 1, wherein said administration of BH4 decreases the plasma phenylalanine concentration of said subject to less than 360 .mu.M.

14. The method of claim 1, wherein said BH4 is administered in a daily dose of between about 1 mg/kg to about 30 mg/kg.

15. The method of claim 1, wherein said BH4 is administered in a daily dose of between about 5 mg/kg to about 30 mg/kg.

16. The method of claim 1, wherein said BH4 is administered as a crystallized form stable for at least 3 months at 40.degree. C. and 75% relative humidity.

17. The method of claim 16, wherein said crystallized form of BH4 comprises at least 99.5% pure (6R)-5,6,7,8-tetrahydrobiopterin.

18. The method of claim 16, wherein said crystallized form of BH4 comprises purified polymorph B, wherein polymorph B, as a hydrochloride salt, exhibits an X-ray powder diffraction pattern with the following characteristic peaks expressed in d-values (A): 8.7 (vs), 5.63 (m), 4.76(m), 4.40 (m), 4.00 (s), 3.23 (s), 3.11 (vs), preferably 8.7 (vs), 6.9 (w), 5.90 (vw), 5.63 (m), 5.07 (m), 4.76 (m), 4.40 (m), 4.15 (w), 4.00 (s), 3.95 (m), 3.52 (m), 3.44 (w), 3.32 (m), 3.23 (s), 3.17 (w), 3.11 (vs), 3.06 (w), 2.99 (w), 2.96 (w), 2.94 (m), 2.87 (w), 2.84 (s), 2.82 (m), 2.69 (w), 2.59 (w), and 2.44 (w).

19. The method of claim 1, further comprising administering to said subject a protein-restricted diet.

20. The method of claim 19, wherein said protein-restricted diet is a phenylalanine-restricted diet wherein the total phenylalanine is restricted to less than 600 mg per day.

21. The method of claim 19, wherein said protein-restricted diet is a phenylalanine-restricted diet wherein the total phenylalanine is restricted to less than 300 mg per day.

22. The method of claim 19, wherein said subject is a pregnant female.

23. The method of claim 19, wherein said subject is an infant between the ages of 0 and 3 years of age.

24. The method of claim 19, wherein said subject is a female of child-bearing age that is contemplating pregnancy.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc